Minimally important differences of the gout impact scale in a randomized controlled trial

Area of Science:

• Rheumatology
• Clinical Trials
• Health Outcomes

Background:

• The Gout Impact Scale (GIS) is a validated instrument for assessing quality of life in gout patients.
• It measures the impact of gout during attacks and overall disease burden.
• Understanding minimally important differences (MIDs) is crucial for interpreting changes in GIS scores.

Purpose of the Study:

• To determine the minimally important differences (MIDs) for the Gout Impact Scale (GIS).
• To assess MIDs for the GIS within the context of a randomized controlled trial (RCT).
• The RCT investigated rilonacept versus placebo for gout flare prevention during allopurinol initiation.

Main Methods:

• A total of 83 patients with at least two gout flares in the past year were included.
• 73 patients with available data at Weeks 8 and 4 formed the MID analysis group.
• Minimally important differences were identified using patient-reported anchor outcomes with a one-step change, and mean score changes and effect sizes (ES) were calculated.

Main Results:

• The mean change in GIS scores for the MID improvement group ranged from -5.24 to -7.61 on a 0-100 scale.
• Effect sizes for the MID improvement group ranged from 0.22 to 0.38 for four GIS scales.
• These findings suggest that an 5-8 point change on the GIS represents a meaningful difference for patients.

Conclusions:

• The minimally important difference (MID) estimates for the Gout Impact Scale (GIS) range from 5 to 8 points.
• These MID values provide valuable benchmarks for interpreting GIS results in future gout clinical trials.
• This study contributes to the better understanding and application of the GIS in evaluating treatment efficacy for gout.